Overview
NICE is unable to make a recommendation on daratumumab (Darzalex) with bortezomib, melphalan and prednisone for untreated multiple myeloma because Janssen did not provide an evidence submission.
Last reviewed: 9 February 2022
Next review: We will review this decision if the company decides to make a submission.